Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Currently, many investors, including us, believe that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Akero Therapeutics Full Press Release Following our shortened report earlier today, this posting is from the Company’s information and its press release. The news demonstrated statistically significant compensated cirrhosis (F4) reversal due to MASH by Both Completer and ITT Analyses at Week 96 in Phase 2b SYMMETRY Study. Akero Therapeutics (AKRO), released preliminary topline week 96 results from SYMMETRY . . . This content is …

Akero Therapeutics Waiting to hear the news from Akero Therapeutics in treating NASH, the company reported Preliminary Topline Results showing statistically significant reversal of compensated Cirrhosis (F4) due to Mash-by both completer and ITT analyses- at week 96 in Phase 2b SYMMETRY Study. Indeed, Akero Therapeutics (

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ (GILD) stock price has been paralyzed for more than three consecutive years.  The long paralysis of Gilead reminds us of Amgen Therapeutics whose stock price was paralyzed at $50 for more than 3 years. The stock rebounded and continued to outperform after we selected it in 2011 Recently, Gilead announced …

Akero Therapeutics Q2 and Business Update Akero Therapeutics (AKRO) reported second-quarter financial results for the period ending June 30, 2024,  and provided business updates. From Akero Therapeutics Andrew Cheng, president and CEO said, “The second quarter of 2024 brought important progress for EFX with the initiation of the . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

From Akero Therapeutics  Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics remarked, "I am delighted to welcome Scott Gangloff to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enrich our company with an invaluable perspective during the late-stage clinical development of efruxifermin.  The entire leadership team looks forward to partnering with Scott to advance …

Akero Therapeutics Akero Therapeutics (AKRO) released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is Non-Alcoholic Steatohepatitis. We will start with NAFLD.   NAFLD The Non-Alcoholic Fatty Liver Disease is caused by excessive fat building up inside the liver cells. It is obvious that what is called Non-Alcoholic fatty liver disease is not caused by alcohol. The liver disease caused by Alcohol is called …

Three Biotech Firm in the NEWS Verona Pharma Verona Pharma plc (VRNA) announced that senior management will present a company overview at the following conferences in November 2023: Jefferies London Healthcare Conference Date: Wednesday, November 15, 2023 Time: 10:00 AM EST / 3:00 PM GMTLocation: London, UK Piper Sandler 35th Annual Healthcare . . . This content is for paid subscribers. Please click here to subscribe or …

Akero Therapeutics Press Release Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip Akero Therapeutics (AKRO)

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Investor webcast on Tuesday, October 10th at 8:00 a.m. ET to present clinical data.   Akero Therapeutics (AKRO) will hold an investor conference . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Akero Therapeutics Akero Therapeutics (AKRO) announced publication in The Lancet Gastroenterology & Hepatology of results from the HARMONY Phase 2b trial in nonalcoholic steatohepatitis (NASH). The paper, which is available online, provides data on the safety, tolerability, and efficacy of once-weekly subcutaneous injections . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

The Stock Market in the New Year It is still too early to tell how the stock market will perform in 2023. However, on Tuesday January 3, 2023 (the first market trading day in 2023), most biotech stocks plummeted, especially, that of the most promising clinical stage small firms' stocks. Today, Wednesday January 4, 2023 ( the second trading day of the new year), the …

Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead Science’s (GILD) stock for years are upgrading it. Demonstrating time and time again its scientific genius in saving millions of people from deadly diseases, Gilead has, at long last, convinced the bearish analysts to turn bullish . . . This content is for paid subscribers. Please click here to subscribe …

Dear Friends and Followers, We confirm our optimism towards the future biotech firms that we selected for investment, including the clinical stage small biotech companies, which also includes biotech stocks that you have never heard about from us.  We  inform you that we have Prohost Letters that will present the selected firms that we believe are promising. One of these Letters, we hope, will be …

Treatments for NASH Madrigal Pharmaceuticals (MDGL) is the second company after Akero Therapeutics (AKRO) to . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals (ABOS) announced that the first clinical-stage monoclonal antibody ACU193 - an anti-amyloid beta oligomer antibody, which selectively targets toxic soluble amyloid beta oligomers (AβOs), has been granted  FDA Fast Track designation for the treatment of early Alzheimer . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis  The efforts spent on treating Non Alcoholic Steatohepatitis (NASH) have reached a promising stage where clinical trial data from the clinical-stage and revenue-generating biotech firms have demonstrated capability of treat NASH. The most promising of these firms we believe, are clinical-stage firms, especially those firms that have already demonstrated capability of regressing fibrosis in …

Rhythm Pharmaceuticals Rhythm Pharmaceuticals (RYTM): After soaring, based on great scientific and drug performance in treating genetic obesity, the selloff of the stock has occurred today after the firm’s announcement and pricing of its public offering of 4.8M shares of its common stock at $26 a share. Akero Therapeutics Akero Therapeutics (

Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company, today released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3). The study met its primary endpoint for both the 50mg . . . This content is for paid subscribers. Please …